Research Solutions
GLS’ passion is advancement in biomedicine and agriculture through fundamental genomics and proteomics research. We continually advance our understanding of the structure and function of genomes and proteomes using our strong experience in multidisciplinary research. We undertake complex research projects, tackle them with robust design and implementation, and employ state-of-the-art hardware and software products and tools to bring about the right solutions. We develop comprehensive research solutions for your problems at any level of complexity within a short time frame.
GLS provides a platform for a variety of bioinformatics research solutions for complex genomics and proteomics problems. They encompass the analyses of splicing mutations causing cryptic splicing of erroneous exons leading to defective genes resulting in disease states, impact of alternative splicing patterns in disease, discovery of disease causing mutations using our patented Functional Genomic Fingerprinting (FGF) technology, and analysis of ncRNA sequences in cancer-associated genomic regions (CAGRs).
FGF technology for discovering defective genes that cause human diseases and adverse drug effects
The discovery of disease-causing genes has been a gargantuan task especially for major illnesses due to the complex involvement of multiple defective genes. Our Functional Genomic Fingerprinting (FGF) Technology is a powerful alternative to current techniques for discovering these genes. By analyzing only the 1% functional regions of the genome within which these mutations occur, we avoid the remaining 99% of the genome. This maximizes efficiency allowing easy identification of defective genes that cause disease. This ability to efficiently find genetic defects has numerous powerful applications in biomedical, pharmaceutical & agricultural industries.
FGF is far more effective in gene discovery efforts than other current techniques such as those based on microarray, HapMap, AFLP, RAPD and positional cloning. FGF has the power to identify the genes responsible for adverse or advantageous effects of pharmaceutical drugs. FGF patents are owned by GLS’ sister company Genome Technologies LLC.
Analysis of splicing mutations and polymorphisms in diseases
Splicing related mutations cause an estimated 50% of human genetic diseases. Analysis of these mutations, cryptic splice sites created by them and the resulting alternative splicing allow critical insights necessary for the advancement of research. GLS has developed a novel algorithm for exploring the effects of splice mutations and polymorphisms in cancer.
Exploring the effect of alternative splicing in disease causation
In addition to its normal functions in creating protein diversity, alternative splicing can lead to defective proteins that cause a wide variety of diseases. GLS is currently developing a suite of proprietary splicing related data analysis tools to explore the normal and disease states by gene expression variations caused by alternative splicing.
Genome-wide MicroRNA profiling using FGF
GLS has developed a unique methodology for miRNA discovery and validation using the Functional Genome Fingerprinting (FGF) technology. MicroRNA profiling and fingerprinting using this technology will have immense applications in the identification of specific signatures associated with diagnosis, prognosis and response to treatment of human tumors.
Genomic analysis for Orphan Crops
GLS, in collaboration with University of Wisconsin’s Horticulture Department, has developed an orphan crop database for analyzing genomic, genetic and breeding data of a number of horticultural crops. This unique bioinformatics resource has the following features: (1) provides integrated access to all available sequence annotations, genetic maps, markers and other information from orphan plant families, (2) has extensive data analysis tools to explore the data, and (3) allows comparative analysis of data from these plants to facilitate research advancements.
|
